Adverum Biotechnologies, Inc. Common Stock
ADVMAdverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing treatments for serious ophthalmic diseases. The company's approach involves using gene therapy to address unmet medical needs, aiming to provide long-term solutions for conditions such as wet age-related macular degeneration and diabetic macular edema. Founded in 2014, Adverum emphasizes innovation in its pursuit to restore or preserve vision through its proprietary delivery platforms.
Company News
Law firm investigating potential securities law violations and fiduciary duty breaches for several companies involved in merger and acquisition transactions.
Eli Lilly announced an acquisition of Adverum Biotechnologies for up to $12.47 per share, focusing on Ixo-vec, a promising gene therapy for wet age-related macular degeneration that could transform treatment from repeated injections to a one-time therapy.
ADMA Biologics, Inc. is expected to report strong sales performance for its marketed products in Q2 2024. The company's supplemental BLA approvals for Asceniv and Bivigam are also likely to have boosted sales. Investors will focus on the company's revenue guidance update and pipeline progress.
Braden Michael Leonard, a significant shareholder of Adverum Biotechnologies, has recently purchased over $1.7 million worth of the company's shares, reflecting his confidence in the firm's prospects.
